{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-262641","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2024-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.411010+00:00","generated_at":"2026-05-29T21:43:38.756755+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Kura Oncology enters $330M upfront collaboration with Kyowa Kirin for ziftomenib; potential milestones up to $1.491B","bullets":["Upfront payment of $330M to Kura; near-term milestones up to $420M including launch of monotherapy R/R setting.","Additional milestones of $513M for hematologic malignancies, plus up to $228M if field expansion option for solid tumors is exercised.","Kyowa Kirin to lead ex-US development/commercialization; Kura leads US with joint profit/cost sharing on US commercialization.","Kura retains rights to next-generation menin inhibitors outside oncology field; exclusivity obligations for both parties.","Tiered double-digit royalties on ex-US sales of ziftomenib on a country-by-country basis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-262641","json":"https://secwatch.observer/filing/0001193125-24-262641.json","markdown":"https://secwatch.observer/filing/0001193125-24-262641.md","text":"https://secwatch.observer/filing/0001193125-24-262641.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312524262641/0001193125-24-262641-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312524262641/d902118d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T21:43:38.756755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}